An experimental oral medication that blocks a scar-forming enzyme. One short trial showed lung capacity held on the highest dose while it fell on placebo; blood-protein readings looked younger, but these remain unvalidated laboratory measures. Against this sit dose-related liver injury and diarrhea. Unapproved everywhere, with no legitimate supply route, and almost all evidence produced by the developer. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 10–25 U/L (men), 8–20 U/L (women) | Earliest signal of drug-induced liver stress |
| AST | 10–25 U/L | Confirms liver-cell injury alongside ALT |
| Total bilirubin | 0.3–1.0 mg/dL | Separates a harmless enzyme rise from true liver injury |
| GGT | 10–25 U/L (men), 8–20 U/L (women) | Most sensitive marker of bile-duct and drug-induced liver stress |
| Alkaline phosphatase | 55–90 U/L | Distinguishes a bile-duct pattern of injury from a liver-cell pattern |
| Potassium | 4.0–4.5 mmol/L | The most frequent adverse event, and low levels lengthen cardiac recovery time |
| eGFR | Above 90 mL/min/1.73 m² | Kidney clearance capacity; below 60 disqualifies from every trial |
| QTcF | Below 430 ms (men), below 450 ms (women) | Detects additive rhythm risk from co-medication and potassium loss |
| FVC, percent predicted | No established target; track change from baseline, where a 2–6% shift is meaningful | The primary efficacy measure in lung fibrosis |
| DLCO, percent predicted | No established target; track change from baseline | Gas transfer across the lung membrane, the second pillar of disease staging |
Cadence: Liver panel and potassium at weeks 2, 4, 8 and 12, then every 3 months; electrocardiogram at weeks 2, 4, 8, 12, 26, 39 and 52; lung function at weeks 4, 12, 26, 39 and 52.